key: cord-0883421-av0t0bdb authors: Tolsdorf, Emma L.; Gojmerac, Christina; Crowson, Jonathan; Frey, Benicio N.; Kapczinski, Flavio; Duarte, Dante title: Conversion to major neurocognitive disorder after COVID‐19 in a woman with bipolar disorder: A 6‐year longitudinal case report date: 2022-05-04 journal: Bipolar Disord DOI: 10.1111/bdi.13192 sha: 71d99b59d2cb2fdb78b1aa5870b2916f6c45a33d doc_id: 883421 cord_uid: av0t0bdb nan The patient is a 78-year-old female with longstanding history of bipolar disorder. Her first documented psychiatric concern was a remote episode of post-partum depression that required hospitalization for approximately 2 weeks in the 1960s. She was treated on and off for the diagnosis of bipolar disorder, and she was noted to be non-compliant with the treatment. Decades later, at age 72, the patient was admitted to St. Joseph's Healthcare Hamilton for two and a half months and was discharged with a diagnosis of bipolar type I mixed episode in 2015. To manage her condition, the patient was prescribed 450 mg of lithium, 4 mg of perphenazine, and 25 mg of amitriptyline daily. Additionally, the patient underwent neuropsychological testing, and she demonstrated weaknesses in processing speed, attention, and executive functioning. The results were described as consistent with moderate white matter changes identified on brain magnetic resonance imaging (MRI), in addition to her psychiatric diagnosis of bipolar disorder. She was diagnosed with minor neurocognitive disorder due to vascular disease. The patient was followed up 1 year later and appeared stable. In the months ahead, the patient was readmitted with a bipolar type I mixed episode. It was the opinion of the physicians treating the patient that it would be beneficial for the patient to be followed in an environment with intense case management and a family health team. Thus, the patient was transferred from an acute psychiatric facility to a psychiatric hospital approximately 8 months later. Following this transition, the patient presented with a bipolar type I mixed episode in the context of noncompliance with medications. She reported several weeks of decreased sleep of 2 to 3 h per night and feeling agitated with racing thoughts and pressured speech. She had difficulty maintaining her personal hygiene and upkeep of her apartment. Repeat neuropsychological testing revealed a stable cognitive profile (Table A1) . She continued to meet criteria for minor neurocognitive disorder due to vascular disease. Two years later (2018), the patient was followed up as an outpatient and inpatient, and once again appeared cognitively stable. She had subjective cognitive concerns but reported functioning independently. Repeat neuropsychological testing showed a stable cognitive profile, and she continued to meet criteria for minor neurocognitive disorder due to vascular disease ( Figure A1 ). On February 2, 2021, the patient tested positive for COVID-19 following an outbreak at a satellite health facility where she was admitted waiting for long-term care due to care needs related to her bipolar disorder. Initially, the patient was asymptomatic. Unfortunately, she did worsen from the infection, and had recurrent fevers and hypoxia around February 12-14, 2021. Due to the consideration of SARS-CoV-2 infection playing a role in her condition, she was also treated with dexamethasone 6 mg IV/PO q24h for up to 10 days and remdesivir 200 mg IV load then 100 mg IV daily for 4 days as part of a research study. Her stay was also complicated by delirium related to hypoxemia as well as complicated urinary tract infection, for which she completed 1 mg ceftazidime every 8 h for 7 days and 1 mg ampicillin every 6 h. Her delirium presented with yelling out, verbal aggression, confusion, disorientation, perseverating, paranoia, and visual hallucinations. After the acute symptoms resolved, she was transferred to a geriatric psychiatry unit for recovery and treatment optimization. The course of the patient's SARS-CoV-2 infection was associated with deterioration of the patient's behavior and mental status. Initially the patient was somewhat agitated at times and yelled intermittently but was overall communicating appropriately. When the patient began to experience symptoms of COVID-19 in mid- Clinical presentation of COVID19 in dementia patients A meta-analysis: the mortality and severity of COVID-19 among patients with mental disorders Long-term cognitive impairment after critical illness COVID-19: ICU delirium management during SARS-CoV-2 pandemic Memory and verbal learning functions in twins with bipolar-I disorder, and the role of information-processing speed The data that support the findings of this study are available on request from the corresponding author, ET. The data are not publicly available due to containing information that could compromise the privacy of the research participant. https://orcid.org/0000-0001-7736-4169Benicio N. Frey https://orcid.org/0000-0001-8267-943XFlavio Kapczinski https://orcid.org/0000-0001-8738-856X